Ultragenyx Pharmaceutical/$RARE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Ticker
$RARE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,294
ISIN
US90400D1081
Website
RARE Metrics
BasicAdvanced
$3.5B
-
-$5.88
0.34
-
Price and volume
Market cap
$3.5B
Beta
0.34
52-week high
$58.73
52-week low
$29.59
Average daily volume
1.1M
Financial strength
Current ratio
2.397
Quick ratio
2.048
Long term debt to equity
543.374
Total debt to equity
588.244
Interest coverage (TTM)
-8.35%
Profitability
EBITDA (TTM)
-477.981
Gross margin (TTM)
-30.87%
Net profit margin (TTM)
-93.04%
Operating margin (TTM)
-86.94%
Effective tax rate (TTM)
-0.45%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-24.51%
Return on equity (TTM)
-377.06%
Valuation
Price to revenue (TTM)
5.805
Price to book
23.82
Price to tangible book (TTM)
-44.81
Price to free cash flow (TTM)
-8.302
Free cash flow yield (TTM)
-12.05%
Free cash flow per share (TTM)
-441.57%
Growth
Revenue change (TTM)
33.46%
Earnings per share change (TTM)
-26.22%
3-year revenue growth (CAGR)
21.18%
3-year earnings per share growth (CAGR)
-5.10%
10-year earnings per share growth (CAGR)
10.73%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
Bulls say / Bears say
Ultragenyx reported a 28% increase in total revenue for Q1 2025 compared to the same period in 2024, indicating strong sales growth. (biospace.com)
The company has set a 2025 revenue guidance of $640 million to $670 million, reflecting confidence in continued growth. (biospace.com)
Ultragenyx's pipeline includes promising candidates like UX143 for osteogenesis imperfecta, with a Phase 3 interim analysis expected in mid-2025. (globenewswire.com)
Despite revenue growth, Ultragenyx reported a net loss of $151 million in Q1 2025, highlighting ongoing profitability challenges. (biospace.com)
The company's R&D expenses in 2024 were $697.9 million, representing 125% of revenue, which may raise concerns about cost management. (stocktitan.net)
Ultragenyx's cash position of $745 million as of December 31, 2024, provides approximately 1.8 years of runway at current burn rates, potentially necessitating future financing. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
RARE News
AllArticlesVideos
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·2 weeks ago
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewsWire·1 month ago
Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $3.5B as of June 18, 2025.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of June 18, 2025.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.